What is the appropriate dosage of racecadotril for adults and children, including adjustments for renal impairment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Racecadotril Dosing

The provided evidence does not contain dosing information for racecadotril; the FDA drug labels 111 are for carvedilol, not racecadotril, and no guidelines address racecadotril dosing. However, based on the available research evidence, I can provide dosing recommendations derived from clinical trials.

Standard Dosing

Adults

  • 1.5 mg/kg orally three times daily as adjunctive therapy to oral rehydration solution 234

Children and Infants (≥3 months of age)

  • 1.5 mg/kg orally three times daily (every 8 hours) as adjunctive therapy to oral rehydration solution 235

This dosing has been validated in:

  • Infants aged 3 months to 4 years (mean age 12.8 months) 2
  • Boys aged 3 to 35 months 3
  • Multiple systematic reviews confirming efficacy across pediatric populations 5

Renal Impairment Adjustments

No specific dosing adjustments for renal impairment are available in the provided evidence. The research studies 23564 do not address dosing modifications for patients with chronic kidney disease or reduced creatinine clearance.

Clinical Considerations for Renal Impairment

Given that racecadotril is an enkephalinase inhibitor with antisecretory properties 4, and considering general principles from the renal dosing guidelines provided 789:

  • Exercise caution when prescribing to patients with moderate to severe renal impairment
  • Start at the lower end of the dosing range if renal function is compromised
  • Monitor closely for adverse effects, as drug accumulation may occur with reduced renal clearance
  • Consider consultation with nephrology or clinical pharmacy for patients with eGFR <30 mL/min/1.73 m²

Important Caveats

The absence of specific renal dosing guidance in the literature represents a significant knowledge gap. The studies demonstrating racecadotril's efficacy 235 did not systematically evaluate or report on patients with renal impairment, nor did they provide pharmacokinetic data in this population.

Until manufacturer-specific guidance or dedicated pharmacokinetic studies in renal impairment become available, prescribers should use racecadotril cautiously in patients with significant renal dysfunction and consider alternative treatments or closer monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.